# Immune Tolerance Study With Aldurazyme® (Laronidase)

> **NCT00741338** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 7 (actual)

## Conditions studied

- Mucopolysaccharidosis I

## Interventions

- **BIOLOGICAL:** Laronidase
- **DRUG:** Cyclosporine A (CsA)
- **DRUG:** Azathioprine (Aza)

## Key facts

- **NCT ID:** NCT00741338
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2014-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00741338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00741338, "Immune Tolerance Study With Aldurazyme® (Laronidase)". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT00741338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*